A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
NCT00000782
Completed
To determine the frequency of delayed-type hypersensitivity (DTH) reactions in HIV-positive patients to two doses of two envelope glycoprotein antigens prepared differently. To determine whether patients who have previously demonstrated a DTH response to intradermal MGStage HIV-1 gp160 IIIB baculovirus (MicroGeneSys) have a reproducible response to a repeat injection of gp160 and whether there is cross-reactivity to intradermal HIV-1 rgp160 IIIB vero cell expressed (Immuno-AG). PER 4/5/95 AMEND... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2021
Locations: Stanford CRS, Palo Alto, California +3 locations
Conditions: HIV Infections
Register for Updates
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
NCT00000829
Completed
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects. To assess whether this vaccine is more immunogenic than placebo following the third vaccination. Children with HIV infection are at increased risk for invasive pneumococcal infection, particularly bacteremia. A large proportion of pneumococcal disease is caused by a limited number of serotypes. The maximu... Read More
Gender:
ALL
Ages:
Between 2 months and 6 months
Trial Updated:
10/27/2021
Locations: Usc La Nichd Crs, Los Angeles, California +32 locations
Conditions: HIV Infections, Pneumococcal Infections
Register for Updates
A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
NCT00000943
Completed
The purpose of this study is to determine the effects of an HIV vaccine (Remune) on the immune system. This study involves patients who have received at least 60 weeks of anti-HIV therapy, either alone or in combination with IL-2, while enrolled in ACTG 328. Remune is an experimental HIV vaccine. To see how the body's immune system reacts, this vaccine will be given with 1 to 3 other vaccines, and skin tests will monitor the body's reaction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2021
Locations: Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City, Iowa +1 locations
Conditions: HIV Infections
Register for Updates
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
NCT00000633
Completed
To determine the safety and immunogenicity of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) in asymptomatic HIV-infected adult volunteers. To compare safety and immunogenicity of two different schedules of gp160 administration. To examine the effects of gp160 and hepatitis B vaccine (Engerix-B) on various markers of viral load and on selected immune parameters. Potentiation of a patient's immune response to HIV might possibly prolong the period of clinical latency and protect... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/26/2021
Locations: Johns Hopkins Adult AIDS CRS, Baltimore, Maryland +1 locations
Conditions: HIV Infections
Register for Updates
Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
NCT00272493
Completed
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly improves cellular immune responses. The purpose of this study is to evaluate the safety and effectiveness of GM-CSF as an adjuvant to improve the immune response to hepatitis B virus (HBV) vaccination in HIV infected individuals.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2021
Locations: Northwestern University CRS, Chicago, Illinois +10 locations
Conditions: HIV Infections
Register for Updates
Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
NCT03889158
Terminated
This study focuses on whether high cardiorespiratory fitness in older adults has a protective effect on the vascular response to acute inflammation in comparison to low-fit older and young adults.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/15/2021
Locations: Integrative Physiology Laboratory, Suite 158, Chicago, Illinois
Conditions: Aging, Inflammation
Register for Updates
Salvage Ovarian FANG™ Vaccine + Bevacizumab
NCT01551745
Completed
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2021
Locations: Mary Crowley Cancer Research Centers, Dallas, Texas
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Register for Updates
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
NCT00801697
Completed
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +9 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
NCT02207920
Completed
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California +6 locations
Conditions: HIV Infections
Register for Updates
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
NCT00865566
Terminated
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men. NOTES: As of April 2013, all vaccinations in this study have been stopped. As of June 2017, this study has been closed.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +21 locations
Conditions: HIV Infections
Register for Updates
Early Immune Responses to Vaccination - A Substudy to HVTN 205
NCT00908323
Completed
HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama Vaccine CRS, Birmingham, Alabama +2 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
NCT01578889
Completed
Some vaccines may work better when given together with another substance known as an adjuvant or when given with an experimental procedure called electroporation (EP). EP is a method where an electric pulse is administered to the same muscle where the vaccine injection is given. The addition of the adjuvant to the vaccine and the delivery with EP may increase a person's immune response to the vaccine. Combination approaches such as a DNA vaccine followed by live vector boost may also increase a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Columbia P&S CRS, New York, New York +4 locations
Conditions: HIV Infections
Register for Updates